The text starts here.

News Release

FOR IMMEDIATE RELEASE
June 1, 2016

AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® in the Field of Gastrointestinal Disease

AbbVie GK
Eisai Co., Ltd.
EA Pharma Co., Ltd.

AbbVie GK (Headquarters: Tokyo, President: James C. Feliciano, “AbbVie”), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and its subsidiary EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Hajime Shimizu, “EA Pharma”), announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-α monoclonal antibody HUMIRA® for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behçet's disease) as of today.

Established in April 2016 through the integration of Eisai's gastrointestinal disease business and AJINOMOTO PHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma has been delegated by Eisai to undertake co-promotion on gastrointestinal disease indications for HUMIRA with Abbvie.

Furthermore, there will be no change to the distribution and sales framework for HUMIRA (AbbVie is the marketing and manufacturing authorization holder for HUMIRA, while Eisai is responsible for distribution). In addition, AbbVie and Eisai will continue co-promotion for HUMIRA of indications outside of the gastrointestinal disease field (treatment of rheumatoid arthritis [including prevention of structural joint damage] and the following diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris, arthropathic psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis).

AbbVie, Eisai and EA Pharma will continue to promote and provide information on the proper use of HUMIRA while making further contributions to improve the quality of life of patients.


<Notes to editors>

1. About HUMIRA

HUMIRA is a fully human anti-TNF-α monoclonal antibody which is approved for the following indications in Japan: “treatment of rheumatoid arthritis (including prevention of structural joint damage) and the following diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris; arthropathic psoriasis; ankylosing spondylitis; polyarticular juvenile idiopathic arthritis; intestinal Behçet's disease; moderate to severe active Crohn's disease as remission induction and maintenance therapy; and moderate to severe ulcerative colitis.”

2. About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

AbbVie GK was established in Japan in 2013. The company employs 900 people, dedicated to developing and delivering treatments in our therapeutic areas focused on immunology, neonatology, liver disease and neuroscience, where we believe we can make a remarkable impact on the lives of patients. For further information, please visit www.abbvie.co.jp.

3. About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our “human health care (hhc)” philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.
For more information about Eisai Co., Ltd., please visit http://www.eisai.com.

4. About EA Pharma

Established in April 2016 through the integration of Eisai's gastrointestinal disease business and AJINOMOTO PHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing.
For further information on EA Pharma Co., Ltd., please visit www.eapharma.co.jp.


Media Inquiries
Public Affairs
AbbVie GK
Tel: +81-(0)3-4577-1112
Public Relations Department
Eisai Co., Ltd.
Tel: +81-(0)3-3817-5120
Public Relations
EA Pharma Co., Ltd.
Tel: +81-(0)3-6280-9802